AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01599559 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-Conformal Radiotherapy (3D-CRT)
Description: Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
Study NCT01367080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWETR10
Description: Amitriptyline hydrochloride 10mg(DWETR10) single dose
Study NCT00482144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDL 450 microseconds
Description: The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
Study NCT00482144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDL 1.5 milliseconds
Description: The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
Study NCT01020422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty
Description: Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
Study NCT06199739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early-Weight bearing
Description: The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
Study NCT03061942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair without synovectomy
Description: 30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
Study NCT03061942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with synovectomy
Description: 30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
Study NCT01562990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, CMC544, Gemcitabine and Oxaliplatine
Description: 2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.
Study NCT03528031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Daily Avocado
Description: Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
Study NCT03611543 — intervention group
Intervention type: DEVICE
Intervention: New investigational curved paddle
Description: X-ray imaging of breast tissue
Study NCT03773588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-Loop propofol Target controlled infusion by Entropy and SPI
Description: Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
Study NCT03773588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop propofol target controlled infusion
Description: Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
Study NCT01184911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine tablets, once
Study NCT03261401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
Study NCT03261401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M5717
Study NCT03261401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
Study NCT04118400 — intervention group
Intervention type: PROCEDURE
Intervention: NIV-NAVA
Description: NAVA mode during Non-invasive ventilation
Study NCT04118400 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal CPAP or NIMV mode
Description: Nasal CPAP or NIMV mode during Non-invasive ventilation
Study NCT01367080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWETR25
Description: Amitriptyline hydrochloride 25mg(DWETR25) single dose
Study NCT00853996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acolbifene hydrochloride
Description: Given orally
Study NCT02538783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Escalating Lottery
Description: Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
Study NCT02439333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)
Description: Nasal high flow therapy
Study NCT02439333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal catheter or Venturi mask
Description: Conventional oxygen therapy
Study NCT03452527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: ICON-1 0.6 mg by intravitreal injection
Study NCT03452527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: aflibercept 2 mg by intravitreal injection
Study NCT03255330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
Study NCT03255330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizol
Description: Standardized treatment
Study NCT03255330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Standardized treatment
Study NCT00312858 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
Description: Prevnar™ 0.5 mL injection
Study NCT02604836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Film-coated oral ibandronate tablet (150 mg) once-monthly
Study NCT03818269 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subcutaneous pressure measurement
Description: Subcutaneous interstitial measurement at D1 and D2
Study NCT00382967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DaTSCAN SPECT imaging
Description: A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
Study NCT00548041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HIV test by oral swab
Description: Eligible subjects underwent rapid HIV testing by oral swab.
Study NCT01087723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Study NCT02416869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular application
Description: Patient receive 4mg of Dexamethasone by intramuscular application
Study NCT02416869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucosal application
Description: Patients receive 4mg of Dexamethasone by submucosal application
Study NCT01087723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT03638635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Abdominal injection of bupivacaine into fascial layer.
Study NCT03638635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Abdominal injection of bupivacaine liposome into fascial layer.
Study NCT00252590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Motivational Feedback
Description: Personalized feedback on health status
Study NCT00252590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Generalized health education related to alcohol use
Study NCT00252590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - treatment as usual
Description: Control group with no additional intervention
Study NCT00802659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
Study NCT04762329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manage My Pain (MMP) digital pain app group
Description: To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
Study NCT01226979 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose endorectal brachytherapy (HDRBT)
Description: The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
Study NCT04122560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 200mg tab
Description: PO dose of 400mg
Study NCT04122560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 200mg tab
Description: PO dose of 400mg
Study NCT04122560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 2 MG/ML
Description: IV dose of 400mg
Study NCT04122560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 2 MG/ML
Description: IV dose of 400mg
Study NCT03188614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Description: The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
Study NCT03188614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluid resuscitation
Description: The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
Study NCT02444585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab
Description: Intended to prevent periprosthetic loss of bone mineral density
Study NCT02444585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Intended to prevent periprosthetic loss of bone mineral density
Study NCT02416869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone submucosal
Description: Patients receive 4mg of submucosal Dexamethasone
Study NCT02416869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8mg Dexamethasone submucosal
Description: Patients receive 8mg of submucosal Dexamethasone
Study NCT02416869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone preoperative
Description: Patients receive 4mg of Dexamethasone preoperatively
Study NCT02416869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4mg Dexamethasone postoperative
Description: Patients receive 4mg of Dexamethasone postoperatively
Study NCT06528600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hymovis ONE
Description: Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
Study NCT03902938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodesign Otologic graft
Description: Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
Study NCT03902938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft temporalis fascia
Description: Patient's mastoid cavity will be covered with covered with autograft.
Study NCT06146309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (2mg/0.05ml)
Description: Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole Sodium 20mg
Description: Twice daily
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium 20mg
Description: Twice daily
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Twice daily
Study NCT06528600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
Study NCT03106233 — intervention group
Intervention type: PROCEDURE
Intervention: LTP flap
Description: A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Twice daily
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin 500 Mg
Description: Twice daily
Study NCT03134378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Twice daily
Study NCT02916992 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan of the thorax
Description: A low dose CT scan of the thorax (2mSv) wil be performed once.
Study NCT02916992 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample for FLCN mutation analyses
Description: A venous punction in order to withdraw 16ml blood is undertaken once.
Study NCT05586737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1 gram rituximab twice with two weeks interval
Study NCT04575935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy
Study NCT04575935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Receive standard of care chemotherapy
Study NCT04575935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Undergo laparotomy
Study NCT04575935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery
Description: Undergo MIS
Study NCT04575935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04575935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04575935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04575935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00861926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin
Description: Ventolin : salbutamol sulfate 100µg
Study NCT00861926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclometasone /formoterol
Description: BDP 100µg/FF 6µg, 1 inhalation bid
Study NCT00004203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00000257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 10% N2O
Study NCT00000257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 20% N2O
Study NCT00000257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 30% N2O
Study NCT00000257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O and 40% N2O
Study NCT04089956 — intervention group
Intervention type: OTHER
Intervention: No interventation
Description: A retrospective cohort Observational study with no intervention
Study NCT02371850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm patch first, then Aveva patch
Description: This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
Study NCT00550160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine plus Artesunate co-administration
Description: Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
Study NCT00550160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus Artesunate co-administration
Description: Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
Study NCT05642546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
Study NCT05642546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo
Study NCT01033773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin
Description: Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
Study NCT01033773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes survival skills self-management education
Description: Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
Study NCT03693716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Anterior Stabilization
Description: All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
Study NCT00867490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan+HCTZ - Phase 1
Description: 4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.